PDS Biotechnology (PDS Biotechnology) Debt-to-EBITDA

: -0.61 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

PDS Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.22 Mil. PDS Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $19.63 Mil. PDS Biotechnology's annualized EBITDA for the quarter that ended in Dec. 2023 was $-38.88 Mil. PDS Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.61.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PDS Biotechnology's Debt-to-EBITDA or its related term are showing as below:

PDSB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.59 Med: -0.29 Max: -0.02
Current: -0.59

During the past 11 years, the highest Debt-to-EBITDA Ratio of PDS Biotechnology was -0.02. The lowest was -0.59. And the median was -0.29.

PDSB's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs PDSB: -0.59

PDS Biotechnology Debt-to-EBITDA Historical Data

The historical data trend for PDS Biotechnology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.04

-0.02

-0.58

-0.59

PDS Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA																-0.32	-0.68	-0.49	-0.60	-0.61

Competitive Comparison

For the Biotechnology subindustry, PDS Biotechnology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PDS Biotechnology Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Debt-to-EBITDA falls into.

PDS Biotechnology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PDS Biotechnology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.222	+	19.629)	/	-40.125
	=	-0.59

PDS Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.222	+	19.629)	/	-38.876
	=	-0.61

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

PDS Biotechnology (NAS:PDSB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

PDS Biotechnology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology (PDS Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

EU6:Germany

Address

25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Executives

Spencer D. Brown	officer: Senior VP, General Counsel	25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill	officer: Chief Financial Officer	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist	director, 10 percent owner	RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King	officer: Interim Chief Financial Office	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev	director	303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk	officer: Principal Accounting Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes	director	C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo	director, 10 percent owner, officer: President/CEO	300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood	officer: Chief Medical Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn	officer: Chief Scientific Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922